INCY News and Press, Incyte Corporation From 12/30/20

- Incyte and Cellenkos will evaluate the combination of ruxolitinib (Jakafi ® ) and CK0804, cord blood-derived T-regulatory cells, in patients with myelofibrosis - Incyte has an exclusive option to acquire sole rights to CK0804 Incyte (Nasdaq:INCY) and Celle...

Merus (MRUS) gains 4% premarket after Incyte (INCY) reports 11% stake or holding of 3.2M shares of the company. The company had 29.09M common shares as of Oct. 30, 2020.Pursuant to the Subscription Agreement, on January 23, 2017, Incyte purchased an aggregate of 3.2M common shares a...

Incyte's (INCY) Phase 3 RUXCOVID study evaluating the safety and efficacy of ruxolitinib (Jakafi) plus standard-of-care (SoC) as a treatment for patients 12 years and older with COVID-19 associated cytokine storm did not meet its primary endpoint. RUXCOVID study was sponsored by Incyte i...

Initial data show that treatment with ruxolitinib plus standard-of-care (SoC) did not prevent complications in patients with COVID-19 associated cytokine storm Incyte (Nasdaq:INCY) today announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of ruxo...

Eli Lilly and Company (LLY) and Incyte (INCY) announce that the New England Journal of Medicine has published peer-reviewed results of the Phase 3 trial for baricitinib with remdesivir in hospitalized patients with COVID-19. The results support the emergency use authorization issued...

Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine INDIANAPOLIS , Dec. 11, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that The ...

The following slide deck was published by Incyte Corporation in conjunction with this event. For further details see: Incyte (INCY) Presents At American Society of Hematology Meeting - Slideshow

- Preliminary safety and efficacy data from Phase 1b firstMIND trial in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) presented today - Also presented today: Long-term subgroup analyses from L-MIND study evaluating tafasitamab combined with lenali...

- Data from the CITADEL program of parsaclisib in patients with follicular, marginal zone and mantle cell lymphomas were accepted for presentation at the 62nd American Society of Hematology Annual Meeting and Exposition (ASH 2020) - Investor conference call and webcast schedul...

Source: Press release"We are pleased both with the response rates and consistency of the results we are seeing in MANIFEST,"says Constellation Pharmaceuticals (CNST) CEO Jigar Raythatha. "In addition, we are excited by results from our translational studies that suggest that CPI-0610 may...